The Food and Drug Administration originally approved Cyltezo in 2017 for the treatment of multiple chronic inflammatory diseases and this latest approval designates it as interchangeable across all of these indications.
Christine Simmon, who also serves as executive director of the Biosimilars Council, has been with the Association for Accessible Medicines for 13 years.